Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995031 | 0.81 | LMNA (0.35) | — | |
| SCHEMBL3291300 | 0.81 | TSHR (0.31) | — | |
| SCHEMBL8618134 | 0.77 | — | — | |
| SCHEMBL8526661 | 0.77 | — | — | |
| SCHEMBL181307 | 0.72 | — | — | |
| SCHEMBL1932322 | 0.70 | — | — | |
| SCHEMBL423846 | 0.70 | LMNA (0.41) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL893441 | 0.70 | MEN1 (0.30) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL7045976 | 0.70 | TSHR (0.32) | — | |
| Ammonia Solution, Strong SCHEMBL8747229 | 0.69 | RIPK1 (0.41) | MEN1CYP3A4ALOX15KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349115-B | A kind of double phenyl hydrophobic monomers and the leak stopping gel based on the monomer | 中国石油化工股份有限公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-106349115-A | Bis-phenyl hydrophobic monomer and plugging gel based on monomer | 中国石油化工股份有限公司 | 2017-01-25 | — | — | CN | disclosed |
| EP-2443087-B1 | DISUBSTITUTED-AMINODIFLUOROSULFINIUM SALTS, PROCESS FOR PREPARING SAME AND METHOD OF USE AS DEOXOFLUORINATION REAGENTS | OMEGACHEM INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-8642798-B2 | Silacycle compounds and methods of use thereof | THE TRUSTEE OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080167468-A1 | using the diastereomeric mixture of Silacycle Compounds for stereoselective synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2006110588-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005120584-A2 | RADIOLABELED ARYLSULFONYL COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005077176-A1 | ANTHOCYANIN COMPOUNDS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | PTGES2, PTGES, PTGS2 | MEN1 2642/4885CYP3A4 683/4885ALOX15 31/4885 |
| US-20080167468-A1 | using the diastereomeric mixture of Silacycle Compounds for stereoselective synthesis | LSS, CYP51A1, DHPS | MEN1 741/4885CYP3A4 103/4885ALOX15 708/4885 |
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | CHAT, PSEN2, PSEN1 | MEN1 4381/4885CYP3A4 3642/4885ALOX15 906/4885 |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | MEN1 593/4885CYP3A4 779/4885ALOX15 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.